Doliracetam
![]() | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H14N2O2 |
| Molar mass | 266.300 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Doliracetam is a nootropic drug (cognition enhancer) from the racetam family used in treatment of epilepsy.[1][2]
According to the Hoechst patent title, it has neuroanabolic action.
See also
References
- ^ EP 62887, Kuch, Heinz & Kruse, Hansjörg, "Indolinone-2 derivatives, process for their preparation and neuro-anabolic mediums containing them", published 1982-10-20, assigned to Hoechst AG
- ^ Fariello RG, Ghelardini C, Di Cesare Mannelli L, Bonanno G, Pittaluga A, Milanese M, Misiano P, Farina C (June 2014). "Broad spectrum and prolonged efficacy of dimiracetam in models of neuropathic pain". Neuropharmacology. 81: 85–94. doi:10.1016/j.neuropharm.2014.01.029. PMID 24486381. S2CID 28039482.
